Literature DB >> 32785649

COVID-19 Vaccines: Should We Fear ADE?

Scott B Halstead1, Leah Katzelnick2,3.   

Abstract

Might COVID-19 vaccines sensitize humans to antibody-dependent enhanced (ADE) breakthrough infections? This is unlikely because coronavirus diseases in humans lack the clinical, epidemiological, biological, or pathological attributes of ADE disease exemplified by dengue viruses (DENV). In contrast to DENV, SARS and MERS CoVs predominantly infect respiratory epithelium, not macrophages. Severe disease centers on older persons with preexisting conditions and not infants or individuals with previous coronavirus infections. Live virus challenge of animals given SARS or MERS vaccines resulted in vaccine hypersensitivity reactions (VAH), similar to those in humans given inactivated measles or respiratory syncytial virus vaccines. Safe and effective COVID-19 vaccines must avoid VAH.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  SARS-CoV-2; T cells; antibody-dependent enhancement (ADE); coronavirus; dengue; dengue hemorrhagic fever; hypersensitivity; immunopathology; vaccine; vaccine adverse events

Mesh：

Substances：

Year:  2020        PMID： 32785649      PMCID： PMC7454712          DOI： 10.1093/infdis/jiaa518

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  19 in total

1.  Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy.

Authors:  Irfan Ullah; Jérémie Prévost; Mark S Ladinsky; Helen Stone; Maolin Lu; Sai Priya Anand; Guillaume Beaudoin-Bussières; Kelly Symmes; Mehdi Benlarbi; Shilei Ding; Romain Gasser; Corby Fink; Yaozong Chen; Alexandra Tauzin; Guillaume Goyette; Catherine Bourassa; Halima Medjahed; Matthias Mack; Kunho Chung; Craig B Wilen; Gregory A Dekaban; Jimmy D Dikeakos; Emily A Bruce; Daniel E Kaufmann; Leonidas Stamatatos; Andrew T McGuire; Jonathan Richard; Marzena Pazgier; Pamela J Bjorkman; Walther Mothes; Andrés Finzi; Priti Kumar; Pradeep D Uchil
Journal:  Immunity       Date:  2021-08-18       Impact factor: 43.474

Review 2.  Overview of Neutralizing Antibodies and Their Potential in COVID-19.

Authors:  José Javier Morales-Núñez; José Francisco Muñoz-Valle; Paola Carolina Torres-Hernández; Jorge Hernández-Bello
Journal:  Vaccines (Basel)       Date:  2021-11-23

3.  The Usefulness of Peripheral Blood Cell Counts to Distinguish COVID-19 from Dengue during Acute Infection.

Authors:  Juan Fidel Osuna-Ramos; José Manuel Reyes-Ruiz; Luis Antonio Ochoa-Ramírez; Luis Adrián De Jesús-González; Rosalío Ramos-Payán; Carlos Noe Farfan-Morales; Alejandra Romero-Utrilla; Efrén Rafael Ríos-Burgueño; José Rodríguez-Millán; Rosa María Del Ángel; Jesús Salvador Velarde-Félix
Journal:  Trop Med Infect Dis       Date:  2022-01-30

Review 4.  Clinical data to be used as a foundation to combat Covid-19 vaccine hesitancy.

Authors:  Robert G Smith
Journal:  J Interprof Educ Pract       Date:  2021-12-11

Review 5.  Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy.

Authors:  Qianqian Zhang; Rong Xiang; Shanshan Huo; Yunjiao Zhou; Shibo Jiang; Qiao Wang; Fei Yu
Journal:  Signal Transduct Target Ther       Date:  2021-06-11

6.  Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo.

Authors:  Alexandra Schäfer; Frauke Muecksch; Julio C C Lorenzi; Sarah R Leist; Melissa Cipolla; Stylianos Bournazos; Fabian Schmidt; Rachel M Maison; Anna Gazumyan; David R Martinez; Ralph S Baric; Davide F Robbiani; Theodora Hatziioannou; Jeffrey V Ravetch; Paul D Bieniasz; Richard A Bowen; Michel C Nussenzweig; Timothy P Sheahan
Journal:  J Exp Med       Date:  2021-03-01       Impact factor: 14.307

7.  Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo.

Authors:  Alexandra Schäfer; Frauke Muecksch; Julio C C Lorenzi; Sarah R Leist; Melissa Cipolla; Stylianos Bournazos; Fabian Schmidt; Anna Gazumyan; Ralph S Baric; Davide F Robbiani; Theodora Hatziioannou; Jeffrey V Ravetch; Paul D Bieniasz; Michel C Nussenzweig; Timothy P Sheahan
Journal:  bioRxiv       Date:  2020-09-15

8.  Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection.

Authors:  Emma S Winkler; Pavlo Gilchuk; Jinsheng Yu; Adam L Bailey; Rita E Chen; Zhenlu Chong; Seth J Zost; Hyesun Jang; Ying Huang; James D Allen; James Brett Case; Rachel E Sutton; Robert H Carnahan; Tamarand L Darling; Adrianus C M Boon; Matthias Mack; Richard D Head; Ted M Ross; James E Crowe; Michael S Diamond
Journal:  Cell       Date:  2021-02-12       Impact factor: 66.850

9.  Expression of SARS-CoV-2 Spike Protein Receptor Binding Domain on Recombinant B. subtilis on Spore Surface: A Potential COVID-19 Oral Vaccine Candidate.

Authors:  Johnny Chun-Chau Sung; Ying Liu; Kam-Chau Wu; Man-Chung Choi; Chloe Ho-Yi Ma; Jayman Lin; Emily Isabel Cheng He; David Yiu-Ming Leung; Eric Tung-Po Sze; Yusuf Khwaja Hamied; Dominic Man-Kit Lam; Keith Wai-Yeung Kwong
Journal:  Vaccines (Basel)       Date:  2021-12-21

Review 10.  Immunological mechanisms of vaccine-induced protection against COVID-19 in humans.

Authors:  Arnaud Marchant; Tobias R Kollmann; Manish Sadarangani
Journal:  Nat Rev Immunol       Date:  2021-07-01       Impact factor: 53.106
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.